Consensus guideline for advanced prostate cancer released by AUA, ASTRO, and SUO

June 25, 2020

The American Urological Association, American Society for Radiation Oncology, and Society of Urologic Oncology have released a joint guideline for advanced prostate cancer to address the growing treatment options and complexity of the paradigm.

AUA updates guideline for surgical management of BPH-related lower urinary tract symptoms

June 25, 2020

The guidelines are an evidence-based clinical reference for the treatment of patients with lower urinary tract symptoms secondary to BPH.

House-passed HEROES Act promises relief for physicians

June 25, 2020

"The HEROES Act makes key improvements to the Medicare Accelerated and Advance Payment Programs," writes Yehuda A. Sugarman of the AACU.

Nerve sparing during robot-assisted radical prostatectomy linked to higher risk of ipsilateral positive surgical margins

June 24, 2020

A real-world analysis found that nerve sparing robot-assisted radical prostatectomy increased the risk of ipsilateral positive surgical margins.

Novel PSMA-targeted radioligand therapy shows promise in mCRPC

June 24, 2020

177Lu-PSMA-617, an investigational radioligand therapy, showed stronger clinical activity than cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel.

Study supports same-day discharge after artificial urinary sphincter insertion

June 23, 2020

Outpatient artificial urinary sphincter insertion is likely a viable option based on an analysis of immediate postoperative complications and pain control.

Photoselective vaporization of the prostate found safe, durably effective

June 23, 2020

Only 1.5% of patients undergo repeat surgical intervention for BPH recurrence.

PROs favor prostatic urethral lift over water vapor ablation for BPH symptoms

June 22, 2020

Patient-reported outcomes showed a superior experience regarding post-procedure BPH symptoms with the UroLift prostatic urethral lift over Rezum tissue ablation with steam injection.

FDA grants relugolix priority review for advanced prostate cancer

June 22, 2020

The FDA has granted a priority review to relugolix for the treatment of patients with advanced prostate cancer

Personalized cancer vaccine combo induces clinical benefit in advanced solid tumors

June 22, 2020

The combination of the personalized cancer vaccine RO719845 and the PD-L1 inhibitor atezolizumab showed strong clinical activity across solid tumors, including bladder cancer and renal cell carcinoma.